BMJ 1998;316:823-828 ( 14 March )

Papers

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)

R C Turner, professor of medicine,  H Millns, statistician,  H A W Neil, lecturer in clinical epidemiology,  I M Stratton, statistician,  S E Manley, biochemist,  D R Matthews, consultant physician in diabetes,  R R Holman, reader in medicine. 

Diabetes Research Laboratories, Nuffield Department of Medicine, University of Oxford, Radcliffe Infirmary, Oxford OX2 6HE

Correspondence to: Professor Turner robert.turner{at}drl.ox.ac.uk

    Abstract
Top
Abstract
References

Objective: To evaluate baseline risk factors for coronary artery disease in patients with type 2 diabetes mellitus.
Design: A stepwise selection procedure, adjusting for age and sex, was used in 2693 subjects with complete data to determine which risk factors for coronary artery disease should be included in a Cox proportional hazards model.
Subjects: 3055 white patients (mean age 52) with recently diagnosed type 2 diabetes mellitus and without evidence of disease related to atheroma. Median duration of follow up was 7.9 years. 335 patients developed coronary artery disease within 10 years.
Outcome measures: Angina with confirmatory abnormal electrocardiogram; non-fatal and fatal myocardial infarction.
Results: Coronary artery disease was significantly associated with increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, and increased triglyceride concentration, haemoglobin A1c, systolic blood pressure, fasting plasma glucose concentration, and a history of smoking. The estimated hazard ratios for the upper third relative to the lower third were 2.26 (95% confidence interval 1.70 to 3.00) for low density lipoprotein cholesterol, 0.55 (0.41 to 0.73) for high density lipoprotein cholesterol, 1.52 (1.15 to 2.01) for haemoglobin A1c, and 1.82 (1.34 to 2.47) for systolic blood pressure. The estimated hazard ratio for smokers was 1.41(1.06 to 1.88).
Conclusion: A quintet of potentially modifiable risk factors for coronary artery disease exists in patients with type 2 diabetes mellitus. These risk factors are increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, raised blood pressure, hyperglycaemia, and smoking.

Key messages

  • Coronary artery disease is the major cause of mortality in patients with type 2 diabetes mellitus

  • Patients without evidence of disease related to atheroma at diagnosis of type 2 diabetes mellitus had an increased standardised mortality ratio compared with the population of the United Kingdom

  • 11% of patients in this study had a myocardial infarction or developed angina over a median of 8 years' follow up

  • The potentially modifiable risk factors for coronary artery disease were increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, hypertension, hyperglycaemia, and smoking; these are also risk factors for coronary artery disease in the general population

  • Evidence is needed on whether modifying these risk factors will reduce coronary artery disease in patients with type 2 diabetes mellitus


    Introduction

Patients with type 2 diabetes mellitus have a twofold to threefold increased incidence of diseases related to atheroma,1 and those who present in their 40s and 50s have a twofold increased total mortality.2 In the United Kingdom the incidence of macrovascular complications in patients with type 2 diabetes mellitus is twice that of microvascular disease.3 The greater mortality in patients with type 2 diabetes mellitus than in the general population cannot be explained only by the presence of the three classic risk factors for coronary artery disease---that is, smoking, hypertension, and an increased plasma cholesterol concentration.4

Previous prospective studies of patients with type 2 diabetes mellitus had comparatively few patients and cardiovascular end points.5-11 Many of these studies have not measured the concentration of low density lipoprotein cholesterol, potentially the most important lipid fraction. 12 13

We report a prospective study of white patients with recently diagnosed type 2 diabetes mellitus. After entry to the United Kingdom prospective diabetes study14 patients were assessed for baseline risk factors after initial treatment by diet for 3 months. The association of coronary artery disease with baseline risk factors has been assessed irrespective of subsequent treatments.

    Subjects and methods

Patients
Between 1977 and 1991, 5102 patients aged 25 to 65 years with type 2 diabetes mellitus based on a fasting plasma glucose concentration >6 mmol/l on two occasions were recruited to the study14; 4775 (94%) had fasting plasma glucose values >7.0 mmol/l, which is consistent with the American Diabetic Association's definition of diabetes. Of the 7108 patients originally referred for entry to the study, 2006 (28%) were excluded. These were of a similar age and sex and had a similar fasting plasma glucose concentration as those patients included in the study. The main reasons for exclusion were myocardial infarction in the previous year, current angina or heart failure, accelerated hypertension, proliferative or preproliferative retinopathy, renal failure with a plasma creatinine concentration >175 µmol/l, other life threatening disease such as cancer, an illness requiring systemic steroids, an occupation which precluded insulin treatment, language difficulties, or ketonuria >3 mmol/l suggestive of insulin dependent diabetes mellitus.

The study was approved by the ethics committee in each of the 23 centres: Radcliffe Infirmary, Oxford; Royal Infirmary, Aberdeen; General Hospital, Birmingham; St George's Hospital and Hammersmith Hospital, London; City Hospital, Belfast; North Staffordshire Royal Infirmary, Stoke on Trent; Royal Victoria Hospital, Belfast; St Helier Hospital, Carshalton; Whittington Hospital, London; Norfolk and Norwich Hospital; Lister Hospital, Stevenage; Ipswich Hospital; Ninewells Hospital, Dundee; Northampton Hospital; Torbay Hospital; Peterborough General Hospital; Scarborough Hospital; Derbyshire Royal Infirmary; Manchester Royal Infirmary; Hope Hospital, Salford; Leicester General Hospital; Royal Devon and Exeter Hospital. All patients gave their informed consent to take part in the study.

The initial treatment by diet for 3 months was completed by 4178 white patients,14 with a mean loss of 5 kg body weight, but only 867 (16.9%) were able to achieve a near normal fasting plasma glucose concentration of <6 mmol/l. Cardiovascular disease was evident in 381 (7.5%) patients, of whom 58 (15.2%) had previous myocardial infarction, 144 (37.8%) a definite electrocardiographic Q wave abnormality on Minnesota coding, 7 (1.8%) angina, 1 (0.3%) heart failure, 120 (31.5%) intermittent claudication, and 51 (13.4%) a previous stroke or transient ischaemic attack. Only 2693 (70.9%) of the 3797 datasets could be analysed for all variables, as biochemical measurements were not undertaken until 1981, and some patients had no valid data for one or more of the other variables. Sufficient data were available from 3055 (80.5%) patients for the final Cox model analysis, and 2161 (56.9%) patients had ophthalmic photographic data available for the assessment of the effect of retinopathy.

After the initial treatment diet, patients were randomly allocated to different treatments according to the protocol of the United Kingdom prospective diabetes study.14 This paper does not include any reference to treatment allocations, actual treatment, or diabetes control during the 10 years of follow up.

                              
View this table:
[in this window]
[in a new window]
 

Table 1 Baseline characteristics in 2693 white patients with no indication of disease related to atheroma. Results are means (SD) or geometric mean (1 SD interval) unless stated otherwise

                              
View this table:
[in this window]
[in a new window]
 

Table 2 Standardised mortality ratios for 5071 patients recently diagnosed with non-insulin dependent diabetes mellitus compared with general population

Follow up, identification, and classification of end points
Patients were seen every three months in the clinics, and any events that were clinically important were noted. To ascertain whether predetermined criteria for the end points were attained two independent doctors received full information on the patients but without details of treatment.14 Any discrepancies between the two doctors were adjudicated by two independent senior doctors. All end points were coded according to ICD-9 (international classification of disease, 9th revision).15

Three aggregate end points were evaluated: coronary artery disease---that is, fatal or non-fatal myocardial infarction or clinical angina---with an abnormal electrocardiogram at rest or after a treadmill test; fatal or non-fatal myocardial infarction; and fatal myocardial infarction.

Baseline risk factors assessment
Height, waist, and hip circumferences were measured, and the smoking status and amount of exercise taken were ascertained by questionnaire.14 Retinopathy was assessed by modified Wisconsin grading of four colour photographs of each eye taken at 30° to the horizontal.14 Blood pressure was recorded as the mean of measurements taken 2 and 9 months after diagnosis with electronic sphygmomanometers. Hypertension was defined as systolic blood pressure >= 160 mm Hg or diastolic blood pressure >= 90 mm Hg, or both, or antihypertensive treatment. After the initial treatment diet, patients were fasted overnight and the following concentrations measured: fasting plasma glucose, haemoglobin A1c, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and insulin. 14 16

Statistical analyses
Data are reported as means (SD), geometric means (1 SD interval), or percentages. Variables for patients included in or excluded from the analyses were compared by t tests, chi 2 tests, or Fisher's exact tests.

Standardised mortality ratio in the patients was calculated from the Office of Population Censuses and Surveys death rates for the general population of England and Wales for the same calendar period, with stratification by sex and age in periods of five years. 17 18

Age was categorised as <50, 50-54, 55-59, or >= 60 years. Continuous variables were grouped into thirds. The effect of potential risk factors on the three aggregate end points was assessed by Cox proportional hazards models,19 with censoring at 10 years' follow up. The relation of single risk factors with events after adjustment for age and sex was assessed in 2693 patients with all risk factors measured. Multivariate selection of risk factors was done by a stepwise procedure after adjustment for age and sex. Estimated hazard ratios are represented graphically, with 95% confidence intervals estimated for each group by treating the relative risks as floating absolute risks so that the appropriate variability for each group is shown.20

                              
View this table:
[in this window]
[in a new window]
 

Table 3 Relation of potential risk factors to cardiac end points after adjustment for age and sex, in 2693 white patients with non-insulin dependent diabetes mellitus

                              
View this table:
[in this window]
[in a new window]
 

Table 4 Stepwise selection of risk factors, adjusted for age and sex, in 2693 white patients with non-insulin dependent diabetes mellitus with dependent variable as time to first event. P values are significance of risk factor after accounting for all other risk factors in model

Baseline biochemical and blood pressure values were corrected for any effects from regression to the mean by examining repeat values at six months in 497 patients who had remained on the diet treatment alone. The effect of a unit increment of risk factors on coronary artery disease (1 mmol/l in low density lipoprotein cholesterol concentration, 0.1 mmol/l in high density lipoprotein cholesterol concentration, 10 mm Hg in systolic blood pressure, and 1% in haemoglobin A1c) was estimated by fitting each factor as a continuous variable in a stepwise selected Cox model, leaving other risk factors as categorical variables and adjusting for regression to the mean. Statistical analyses were performed using SAS version 6.1. 

    Results

Table 1 shows the baseline risk factors assessed for the 2693 white patients who had no previous indication of disease related to atheroma and had complete data when studied after the initial treatment diet. The men who were entered into the United Kingdom prospective diabetes study but excluded from this analysis because of previous cardiovascular disease were older (mean age 56 (SD7) years), had higher systolic blood pressure (mean 141(20) mm Hg), were more likely to be hypertensive (46%), and were more likely to be smokers (10% had never smoked, 51% were ex-smokers, and 39% were current smokers) (P<0.01 for each). Women who were excluded from the study were also older (mean age 56 (8) years) and had higher systolic blood pressure (mean 145 (20) mm Hg) (P<0.01 for each). Baseline concentrations of total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol, and triglyceride did not differ in subjects according to the presence of disease related to atheroma (P>0.01).

Standardised mortality ratio
During the first five years of the study the standardised mortality ratio was not very different from that in the general population, possibly because patients with life threatening illnesses were excluded from the study (table 2). After the first five years of the study patients with type 2 diabetes mellitus had an increased total mortality compared with the general population.

Relation of baseline risk factors with adjustment for age and sex
Table 3 shows the relation of potential risk factors, stratified by thirds, to coronary artery disease in 280 patients with end points. Important variables were low density lipoprotein cholesterol concentration, high density lipoprotein cholesterol concentration, and also triglyceride concentration, haemoglobin A1c, systolic blood pressure, fasting plasma glucose concentration, and smoking; each of these had a positive association except high density lipoprotein cholesterol concentration. Similar associations were seen for fatal or non-fatal myocardial infarction (192 patients with end points) and fatal myocardial infarction (79 patients with end points). Retinopathy was associated with fatal myocardial infarction (P=0.005) but not with fatal or non-fatal myocardial infarction (P=0.124) or with coronary artery diseases (P=0.082).

Stepwise selection of risk factors
Table 4 shows the selected risk factors with P values from the stepwise multivariate Cox models. Factors that were not important were body mass index, waist to hip ratio, exercise, triglyceride concentration, and fasting plasma glucose or insulin concentration, and these were not included in the final model. The exclusion of triglyceride concentration and not high density lipoprotein cholesterol concentration was not due solely to imprecision of measurements, since baseline triglyceride concentration correlated with the values 6 months later in subjects randomised to, and remaining on, the diet (rs=0.72 (95% confidence interval 0.68 to 0.76)). This correlation was greater than the correlation between repeated high density lipoprotein measurements (rs=0.52 (0.45 to 0.58)). Baseline triglyceride concentration correlated with high density lipoprotein cholesterol concentration (rs=-0.27 (P<0.0001)). No significant interaction term was identified between high density lipoprotein cholesterol concentration and low density lipoprotein cholesterol concentration.

Estimated hazard ratios
Table 5 and the figure show the Cox model estimated hazard ratios for age and sex and the stepwise selected variables for coronary artery disease in 3055 patients (335 with a coronary artery disease). A similar pattern of hazard ratios was seen for fatal or non-fatal myocardial infarction (233 patients with an event) and fatal myocardial infarction (103 patients with an event). Although diastolic blood pressure had a stronger relation than systolic blood pressure with any myocardial infarction or fatal myocardial infarction, replacement by systolic blood pressure did not affect the results.

                              
View this table:
[in this window]
[in a new window]
 

Table 5 Estimated hazard ratios (95% confidence intervals) for coronary artery disease in 3055 patients, fitting same explanatory variables for all three dependent variables


View larger version (26K):
[in this window]
[in a new window]
  		Estimated hazard ratios for significant risk factors for coronary artery disease occurring in 335 out of 3055 diabetic patients (expressed as floating absolute risks)

Fitting the risk factors for coronary artery disease as continuous variables, with allowance for regression to mean, indicated that for each increment of 1 mmol/l in low density lipoprotein cholesterol concentration there was a 1.57-fold (95% confidence interval 1.37 to 1.79) increased risk of coronary artery disease. For each positive increment of 0.1 mmol/l in high density lipoprotein cholesterol concentration there was a 0.15-fold (0.08 to 0.22) decrease in risk, for each increment of 10 mm Hg in systolic blood pressure a 1.15-fold (1.08 to 1.23) increase, and for each increment of 1% in haemoglobin A1c a 1.11-fold (1.02 to 1.20) increase in risk.

The retinopathy grading was not significantly related to any of the three aggregate end points when added to the multivariate models, including age, sex, and the other risk factors in table 4.

    Discussion

This study shows that in patients with type 2 diabetes mellitus increased concentrations of low density lipoprotein cholesterol, decreased concentrations of high density lipoprotein cholesterol, hyperglycaemia, hypertension, and smoking (all measured on completion of a treatment diet after diagnosis), are risk factors for coronary artery disease, defined as fatal and non-fatal myocardial infarction or angina. Previous studies have shown inconsistent results, being dependent on univariate analyses in small studies, with few patients having clinical end points. Total cholesterol concentration was reported to be a risk factor in some 5 7 21 but not other studies, 6 8 22 and most had not measured both low density lipoprotein cholesterol and high density lipoprotein cholesterol concentrations. Hyperglycaemia was similarly reported as a risk factor in some 5 6 8 11 21 22 but not other studies,7 and hypertension similarly in some 5 22 but not other studies. 6-8 11 21 The present study shows that patients with type 2 diabetes mellitus have the same risk factors for coronary artery disease as the general population.23 This study confirms that patients with non-insulin diabetes mellitus have an increased total mortality compared with the general population, although this was not apparent in the initial 5 years, probably because diabetic patients with life threatening illness were excluded from the United Kingdom prospective diabetes study.

Major risk factors
Low density lipoprotein and total cholesterol ---An increased concentration of low density lipoprotein cholesterol or total cholesterol at baseline was a major risk factor for coronary artery disease. This is similar to the general population. 13 24 25 Increased concentrations of low density lipoprotein cholesterol may be more pathogenic in patients with type 2 diabetes mellitus than in non-diabetic patients because of the presence of small dense low density lipoprotein cholesterol particles26 and oxidation of glycated low density lipoprotein cholesterol.27 The 1.57 increased risk for an increment of 1 mmol/l in low density lipoprotein cholesterol concentration equates to a 36% risk reduction for a decrement of 1 mmol/l , similar to the 31% risk reduction achieved with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in men with hypercholesterolaemia.13 The subgroup analysis of the simvastatin study28 showed that the diabetic patients had similar protection to that of non-diabetic patients.25 A decreased concentration of high density lipoprotein cholesterol was an independent risk factor for coronary artery disease. The 15% decrease in the risk of coronary artery disease associated with a 0.1 mmol/l increment in high density lipoprotein cholesterol concentration is compatible with the 8-12% reduction reported from prospective American studies.29 Triglyceride concentration was a risk factor for coronary artery disease after adjustment for age and sex, but it was not an independent risk factor when the other variables were included in the model. This is in accord with other studies, possibly because of the greater biological variability of triglyceride than high density lipoprotein cholesterol measurements.30 However, we found over 6 months that the concentration of high density lipoprotein cholesterol was more variable than that of triglyceride, possibly because of less precision with the assay (coefficient of variation 6% v 2%) and because patients were receiving dietary advice and had a more uniform dietary intake than in the general population. As control of plasma triglyceride and high density lipoprotein cholesterol concentrations is interlinked through lipoprotein lipase and hepatic lipase activities, it may not be feasible to separate the contributions of triglyceride and high density lipoprotein cholesterol to coronary artery disease. Postprandial triglyceride values may have an additional atherogenic role to the fasting values that were measured.31

Haemoglobin A1c ---There was an increase in risk of coronary artery disease with haemoglobin A1c of >6.2%, the upper range of normal values, in accord with other studies which suggest that glycaemia above the normal range gives an increased risk for macrovascular disease. 32 33 If glycation of proteins was a major pathogenic factor for coronary artery disease the increased risk would be expected to be proportional to the degree of hyperglycaemia.34 The study showed an increased risk of 11% for each increment of 1% in haemoglobin A1c, similar to the 10% increase in mortality from ischaemic heart disease for an increment of 1% in haemoglobin A1c reported in Wisconsin.35

Blood pressure ---Increased blood pressure was also a major risk factor for coronary artery disease, with a 15% increased risk for an increase in systolic blood pressure of 10 mm Hg, which was similar to that reported in the general population.36 Increased blood pressure was a major risk factor for fatal myocardial infarction. This could be because hypertension is a major additional burden to the heart when myocardial infarction ensues. The hypertension in diabetes study in 1148 patients in a factorial design is evaluating whether strict blood pressure control will prevent complications.37

Retinopathy--- Retinopathy at diagnosis was not a risk factor for cardiovascular disease in a multivariate analysis, although retinopathy was a risk factor for fatal myocardial infarction when only age and sex were adjusted for. Since both retinopathy38 and microalbuminuria39 are associated with hyperglycaemia and hypertension, which are also risk factors for coronary artery disease, the previously described association of retinopathy and microalbuminuria with subsequent cardiovascular mortality might reflect the longstanding hypertension and hyperglycaemia that induced both macrovascular and microvascular disease.

Risk factors in type 2 diabetes mellitus
Risk factors for development of coronary artery disease in the general population may not apply once diabetes has developed. Obesity and central obesity,40 decreased physical activity,41 and raised insulin concentrations42 provide an increased risk for cardiovascular disease, but in patients with type 2 diabetes mellitus we found that none of these were major risk factors. These variables are also risk factors for diabetes,43-45 but this study indicates that once diabetes has developed, hypertension, increased concentrations of low density lipoprotein or decreased concentrations of high density lipoprotein cholesterol and hyperglycaemia measured at baseline are greater risk factors for coronary artery disease than these precipitating factors.

Syndrome X, the association of raised concentrations of glucose, insulin, and triglyceride, decreased concentrations of high density lipoprotein cholesterol, and increased blood pressure, describes a combination of previously reported risk factors for coronary artery disease.46 In the general population the combination of upper body obesity, glucose intolerance, hypertriglyceridaemia, and hypertension has been termed the deadly quartet.47 However, a quintet of increased concentrations of low density lipoprotein and decreased concentrations of high density lipoprotein cholesterol, hypertension, hyperglycaemia, and smoking is probably more relevant in patients with type 2 diabetes mellitus.

    Acknowledgments

The cooperation of the patients and many NHS and non-NHS staff at the centres is much appreciated. We thank Professor Eva Kohner, Mr Steve Aldington, Ms Ivy Samuel, and Mrs Caroline Wood for help with the manuscript.

Contributors: RCT and RRH coordinated the study, HM and IMS carried out the statistical analyses, HAWN provided epidemiological advice, DRM coordinated the assessment of clinical end points, and SEM provided biochemical advice. All authors wrote the paper. RCT will act as guarantor of the study.

Funding: This study received grants from the Medical Research Council; British Diabetic Association; the Department of Health; the National Eye Institute and the National Institute of Digestive, Diabetes and Kidney Disease in the National Institutes of Health, United States; the British Heart Foundation; the Health Promotion Research Trust; Charles Wolfson Charitable Trust; the Alan and Babette Sainsbury Trust; the Clothworkers' Foundation; Oxford University Medical Research Fund Committee; and pharmaceutical companies, including Novo-Nordisk, Bayer, Bristol Myers Squibb, Hoechst, Lilly, Lipha, and Farmitalia Carlo Erba. Additional funding came from Boehringer Mannheim, Becton Dickinson, Owen Mumford, Securicor, Kodak, and Cortecs Diagnostics.

Conflict of interest: None.

    References
Top
Abstract
References

  1. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up. Diabetes 1974; 23: 105-111[Medline].
  2. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 123-131[Medline].
  3. United Kingdom Prospective Diabetes Study Group. UKPDS 17. A nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-145[Abstract/Free Full Text].
  4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444[Abstract].
  5. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycaemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-1309[Abstract].
  6. Kuusisto J, Mykkänen L, Pyörälä K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967[Abstract].
  7. Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304[Medline].
  8. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993; 36: 1175-1184[Medline].
  9. Butler WJ, Ostrander LD, Carman WJ, Lamphiear DE. Mortality from coronary heart disease in the Tecumseh study. Long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985; 121: 541-547[Abstract/Free Full Text].
  10. Heyden S, Heiss G, Bartel AG, Hames CG. Sex differences in coronary mortality among diabetics in Evans County, Georgia. J Chronic Dis 1980; 33: 265-273[Medline].
  11. Laakso M, Lehto S, Penttila I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993; 88: 1421-1430[Abstract/Free Full Text].
  12. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363-366[Abstract/Free Full Text].
  13. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307[Abstract/Free Full Text].
  14. United Kingdom Prospective Diabetes Study Group. UKPDS VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890[Medline].
  15. World Health Organisation. International classification of procedures in medicine. Geneva: World Health Organisation , 1978.
  16. United Kingdom Prospective Diabetes Study Group. UKPDS XI. Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabetic Med 1994; 11: 534-534[Medline].
  17. Population Censuses and Surveys Office. Mortality statistics: review of the registrar general on deaths in England and Wales. London: HMSO, 1994. 
  18. Coleman MP, Herman C, Douglas A. Person-years (PYRS): a FORTRAN program for cohort study analysis. Lyons: International Agency for Research on Cancer, 1989. 
  19. Cox DR. Regression models and life-tables. J R Stat Soc Series B 1972; 34: 187-201.
  20. Easton DF, Peto J, Babiker AG. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 1991; 10: 1025-1035[Medline].
  21. Lehto S, Ronnemaa T, Haffner SM, Pyörälä K, Kallio V, Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997; 48: 1354-1359.
  22. Walters DP, Gatling W, Houston AC, Mullee MA, Julious SA, Hill RD. Mortality in diabetic subjects: an eleven-year follow-up of a community-based population. Diabetic Med 1994; 11: 968-973[Medline].
  23. Kannel WB, Wilson PW. An update on coronary risk factors. Med Clin North Am 1995; 79: 951-971[Medline].
  24. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994; 308: 367-372[Abstract/Free Full Text].
  25. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389[Medline].
  26. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss PM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-1921[Abstract].
  27. Kawamura M, Heinecke JW, Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. J Clin Invest 1994; 94: 771-778.
  28. Pyörälä K, Pedersen TR, Kjekshus J. The effect of cholesterol lowering with simvastatin on coronary artery diseases in diabetic patients with cornary heart disease. Diabetes 1995; 44(suppl): 35A.
  29. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15[Abstract/Free Full Text].
  30. Schectman G, Sasse E. Variability of lipid measurements: relevance for the clinician. Clin Chem 1993; 39: 1495-1503[Abstract].
  31. Stensvold I, Tverdal A, Urdal P, Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 1993; 307: 1318-1322.
  32. Jarrett RJ, Keen H. Hyperglycaemia and diabetes mellitus. Lancet 1976; 2: 1009-1012[Medline].
  33. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt J. A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. Diabetes Care 1997; 20: 935-942[Abstract].
  34. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-1843[Abstract].
  35. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268[Abstract].
  36. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774[Medline].
  37. Hypertension in Diabetes Study Group. HDS 4: therapeutic requirements to maintain tight blood pressure control. Diabetologia 1996; 39: 1554-1561[Medline].
  38. Stratton IM, Kohner E, Aldington S, Matthews DR, Turner RC. Prevalence of diabetic retinopathy at diagnosis of non-insulin dependent diabetes in 2964 white Caucasian patients and association with hypertension, hyperglycaemia and impaired beta-cell function. Diabetes 1995; 43: S434.
  39. United Kingdom Prospective Diabetes Study Group. UKPDS X. Urinary albumin excretion over 3 years in diet-treated type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36: 1021-1029[Medline].
  40. Byers T. Body weight and mortality. N Engl J Med 1995; 333: 723-724[Free Full Text].
  41. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, et al. Body weight and mortality among women. N Engl J Med 1995; 333: 677-685[Abstract/Free Full Text].
  42. Desprès JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957[Abstract/Free Full Text].
  43. Modan M, Karasik A, Halkin H, Fuchs Z, Lusky A, Shitrit A, et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response. The Israel study of glucose intolerance, obesity and hypertension. Diabetologia 1986; 29: 82-89[Medline].
  44. Desprès JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511[Abstract/Free Full Text].
  45. Manson JE, Rimm EB, Stampfer MJ, Colditz GA, Willett WC, Krolewski AS, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet 1991; 338: 774-778[Medline].
  46. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607[Abstract].
  47. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520[Abstract].

(Accepted 24 October 1997)

© BMJ 1998
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Articles

Two groups were different in cardiovascular risk study
Malvinder S Parmar
BMJ 2003 327: 290-291. [Extract] [Full Text]

Five modifiable risk factors for coronary artery disease exist in type 2 diabetes
BMJ 1998 316: 0. [Full Text]

This article has been cited by other articles:

  • Huelsmann, M., Neuhold, S., Strunk, G., Moertl, D., Berger, R., Prager, R., Abrahamian, H., Riedl, M., Pacher, R., Luger, A., Clodi, M. (2008). NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 0: ehn334v1-6 [Abstract] [Full text]  
  • Elkeles, R. S., Godsland, I. F., Feher, M. D., Rubens, M. B., Roughton, M., Nugara, F., Humphries, S. E., Richmond, W., Flather, M. D., for the PREDICT Study Group, (2008). Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study. Eur Heart J 0: ehn279v1-8 [Abstract] [Full text]  
  • Karalliedde, J., Gnudi, L. (2008). ACCORD and ADVANCE: a tale of two studies on the merits of glycaemic control in type 2 diabetic patients. Nephrol Dial Transplant 23: 1796-1798 [Full text]  
  • Kleefstra, N., Landman, G. W.D., Houweling, S. T., Ubink-Veltmaat, L. J., Logtenberg, S. J.J., Meyboom-de Jong, B., Coyne, J. C., Groenier, K. H., Bilo, H. J.G. (2008). Prediction of Mortality in Type 2 Diabetes From Health-Related Quality of Life (ZODIAC-4). Diabetes Care 31: 932-933 [Abstract] [Full text]  
  • Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 51: 1512-1524 [Full text]  
  • Betteridge, D. J., DeFronzo, R. A., Chilton, R. J. (2008). PROactive: time for a critical appraisal. Eur Heart J 29: 969-983 [Abstract] [Full text]  
  • Carrier, J. (2008). Aerobic plus resistance training was more effective than either alone for glycaemic control in type 2 diabetes. Evid. Based Nurs. 11: 48-48 [Full text]  
  • Brunzell, J. D., Davidson, M., Furberg, C. D., Goldberg, R. B., Howard, B. V., Stein, J. H., Witztum, J. L. (2008). Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 31: 811-822 [Full text]  
  • Turchin, A., Shubina, M., Chodos, A. H., Einbinder, J. S., Pendergrass, M. L. (2008). Effect of Board Certification on Antihypertensive Treatment Intensification in Patients With Diabetes Mellitus. Circulation 117: 623-628 [Abstract] [Full text]  
  • Stirban, A. O., Tschoepe, D. (2008). Should We Be More Aggressive in the Therapy Against Cardiovascular Risk Factors?: Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill?. Diabetes Care 31: S226-S228 [Abstract] [Full text]  
  • Lund, S. S, Tarnow, L., Frandsen, M., Smidt, U. M, Pedersen, O., Parving, H.-H., Vaag, A. A (2008). Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. Eur J Endocrinol 158: 35-46 [Abstract] [Full text]  
  • Fharm, E., Rolandsson, O., Weinehall, L. (2008). Guidelines improve general trend of lowered cholesterol levels in type 2 diabetes patients in spite of low adherence. Scand J Public Health 36: 69-75 [Abstract]  
  • Peters, A. L. (2008). Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes. Clin. Diabetes 26: 3-7 [Abstract] [Full text]  
  • Nesto, R. W. (2008). LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?. Clin. Diabetes 26: 8-13 [Abstract] [Full text]  
  • Hu, G., Jousilahti, P., Tuomilehto, J. (2007). Joint effects of history of hypertension at baseline and type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 28: 3059-3066 [Abstract] [Full text]  
  • Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J.P., Bittner, V., Fruchart, J.-C., the Treating to New Targets Investigators, (2007). HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. NEJM 357: 1301-1310 [Abstract] [Full text]  
  • Batty, G. D., Kivimaki, M., Smith, G. D., Marmot, M. G., Shipley, M. J. (2007). Obesity and Overweight in Relation to Mortality in Men With and Without Type 2 Diabetes/Impaired Glucose Tolerance: The original Whitehall Study. Diabetes Care 30: 2388-2391 [Full text]  
  • Cheung, N., Wang, J. J., Klein, R., Couper, D. J., Sharrett, A. R., Wong, T. Y. (2007). Diabetic Retinopathy and the Risk of Coronary Heart Disease: The Atherosclerosis Risk in Communities Study. Diabetes Care 30: 1742-1746 [Abstract] [Full text]  
  • Dasu, M. R., Devaraj, S., Jialal, I. (2007). High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am. J. Physiol. Endocrinol. Metab. 293: E337-E346 [Abstract] [Full text]  
  • Millett, C., Gray, J., Saxena, S., Netuveli, G., Majeed, A. (2007). Impact of a pay-for-performance incentive on support for smoking cessation and on smoking prevalence among people with diabetes. CMAJ 176: 1705-1710 [Abstract] [Full text]  
  • The Mount Hood 4 Modeling Group, (2007). Computer Modeling of Diabetes and Its Complications: A report on the Fourth Mount Hood Challenge Meeting. Diabetes Care 30: 1638-1646 [Abstract] [Full text]  
  • Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Berghe, G. V. d., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J Suppl 9: C3-C74 [Full text]  
  • McAuley, P. A., Myers, J. N., Abella, J. P., Tan, S. Y., Froelicher, V. F. (2007). Exercise Capacity and Body Mass as Predictors of Mortality Among Male Veterans With Type 2 Diabetes. Diabetes Care 30: 1539-1543 [Abstract] [Full text]  
  • Avogaro, A., Giorda, C., Maggini, M., Mannucci, E., Raschetti, R., Lombardo, F., Spila-Alegiani, S., Turco, S., Velussi, M., Ferrannini, E., for the Diabetes and Informatics Study Group, Asso, (2007). Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women: Impact of microvascular complications, treatment, and geographic location. Diabetes Care 30: 1241-1247 [Abstract] [Full text]  
  • (2007). Statins OK for Most to Reduce MI Risk. DOC News 4: 4-4 [Full text]  
  • Wada, T., Naito, M., Kenmochi, H., Tsuneki, H., Sasaoka, T. (2007). Chronic Nicotine Exposure Enhances Insulin-Induced Mitogenic Signaling via Up-Regulation of {alpha}7 Nicotinic Receptors in Isolated Rat Aortic Smooth Muscle Cells. Endocrinology 148: 790-799 [Abstract] [Full text]  
  • Abrahamson, M. J. (2007). A 74-Year-Old Woman With Diabetes. JAMA 297: 196-204 [Abstract] [Full text]  
  • Authors/Task Force Members, , Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., Malmberg, K., Priori, S., Ostergren, J., Tuomilehto, J., Thrainsdottir, I., Other Contributors, , Vanhorebeek, I., Stramba-Badiale, M., Lindgren, P., Qiao, Q., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Deckers, J. W., Bertrand, M., Charbonnel, B., Erdmann, E., Ferrannini, E., Flyvbjerg, A., Gohlke, H., Juanatey, J. R. G., Graham, I., Monteiro, P. F., Parhofer, K., Pyorala, K., Raz, I., Schernthaner, G., Volpe, M., Wood, D. (2007). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136 [Full text]  
  • Erdei, N., Bagi, Z., Edes, I., Kaley, G., Koller, A. (2007). H2O2 increases production of constrictor prostaglandins in smooth muscle leading to enhanced arteriolar tone in Type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 292: H649-H656 [Abstract] [Full text]  
  • Wierzbicki, A. S. (2006). Diabetic dyslipidaemia: the triad. Eur Heart J Suppl 8: F30-F33 [Abstract] [Full text]  
  • Kobayashi, T., Hayashi, Y., Taguchi, K., Matsumoto, T., Kamata, K. (2006). ANG II enhances contractile responses via PI3-kinase p110{delta} pathway in aortas from diabetic rats with systemic hyperinsulinemia. Am. J. Physiol. Heart Circ. Physiol. 291: H846-H853 [Abstract] [Full text]  
  • Picchi, A., Gao, X., Belmadani, S., Potter, B. J., Focardi, M., Chilian, W. M., Zhang, C. (2006). Tumor Necrosis Factor-{alpha} Induces Endothelial Dysfunction in the Prediabetic Metabolic Syndrome. Circ. Res. 99: 69-77 [Abstract] [Full text]  
  • Hokanson, J. M., Anderson, R. L., Hennrikus, D. J., Lando, H. A., Kendall, D. M. (2006). Integrated Tobacco Cessation Counseling in a Diabetes Self-management Training Program: A Randomized Trial of Diabetes and Reduction of Tobacco.. The Diabetes Educator 32: 562-570 [Abstract] [Full text]  
  • Hood, R., Valentine, V., Mac, S., Polonsky, W. H (2006). Use of Exenatide in Patients With Type 2 Diabetes. Diabetes Spectr. 19: 181-186 [Abstract] [Full text]  
  • Balasubramanyam, A., Hinnen, D., Polonsky, W. (2006). Cardiovascular Event Prevention in the Person With Type 2 Diabetes: Case Examples for Identifying and Treating Multiple Risks. The Diabetes Educator 32: 163S-173S [Full text]  
  • Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., Waters, D., for the Treating to New Targets Investigators, (2006). Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study.. Diabetes Care 29: 1220-1226 [Abstract] [Full text]  
  • Authors/Task Force Members, , Fox, K., Garcia, M. A. A., Ardissino, D., Buszman, P., Camici, P. G., Crea, F., Daly, C., De Backer, G., Hjemdahl, P., Lopez-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Zamorano, J. L, Andreotti, F., Becher, H., Dietz, R., Fraser, A., Gray, H., Antolin, R. A. H., Huber, K., Kremastinos, D. T., Maseri, A., Nesser, H.-J., Pasierski, T., Sigwart, U., Tubaro, M., Weis, M. (2006). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27: 1341-1381 [Full text]  
  • Einarsdottir, E., Mayans, S., Ruikka, K., Escher, S. A., Lindgren, P., Agren, A., Eliasson, M., Holmberg, D. (2006). Linkage but Not Association of Calpain-10 to Type 2 Diabetes Replicated in Northern Sweden. Diabetes 55: 1879-1883 [Abstract] [Full text]  
  • Wei, L, Murphy, M J, MacDonald, T M (2006). Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart 92: 746-751 [Abstract] [Full text]  
  • (2006). Abstracts. Heart 92: A4-A121 [Full text]  
  • Mooradian, A. D., Haas, M. J., Wong, N. C. W. (2006). The Effect of Select Nutrients on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I Levels. Endocr. Rev. 27: 2-16 [Abstract] [Full text]  
  • Solano, M. P., Goldberg, R. B. (2006). Lipid Management in Type 2 Diabetes. Clin. Diabetes 24: 27-32 [Abstract] [Full text]  
  • Bloomgarden, Z. T. (2005). 2nd International Symposium on Triglycerides and HDL: Metabolic syndrome. Diabetes Care 28: 2577-2584 [Full text]  
  • Selvin, E., Coresh, J., Golden, S. H., Brancati, F. L., Folsom, A. R., Steffes, M. W. (2005). Glycemic Control and Coronary Heart Disease Risk in Persons With and Without Diabetes: The Atherosclerosis Risk in Communities Study. Arch Intern Med 165: 1910-1916 [Abstract] [Full text]  
  • Staels, B., Fruchart, J.-C. (2005). Therapeutic Roles of Peroxisome Proliferator-Activated Receptor Agonists. Diabetes 54: 2460-2470 [Abstract] [Full text]  
  • Reed, R. L., Revel, A. D., Carter, A. O., Saadi, H. F., Dunn, E. V. (2005). A controlled before-after trial of structured diabetes care in primary health centres in a newly developed country. Int J Qual Health Care 17: 281-286 [Abstract] [Full text]  
  • Bagi, Z., Erdei, N., Toth, A., Li, W., Hintze, T. H., Koller, A., Kaley, G. (2005). Type 2 Diabetic Mice Have Increased Arteriolar Tone and Blood Pressure: Enhanced Release of COX-2-Derived Constrictor Prostaglandins. Arterioscler. Thromb. Vasc. Bio. 25: 1610-1616 [Abstract] [Full text]  
  • Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., for the GLAI Study Investigators, (2005). A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia. Diabetes Care 28: 1547-1554 [Abstract] [Full text]  
  • Sone, H., Mizuno, S., Fujii, H., Yoshimura, Y., Yamasaki, Y., Ishibashi, S., Katayama, S., Saito, Y., Ito, H., Ohashi, Y., Akanuma, Y., Yamada, N., the Japan Diabetes Complications Study Group, (2005). Is the Diagnosis of Metabolic Syndrome Useful for Predicting Cardiovascular Disease in Asian Diabetic Patients?: Analysis from the Japan Diabetes Complications Study. Diabetes Care 28: 1463-1471 [Abstract] [Full text]  
  • Bloomgarden, Z. T. (2005). The European Association for the Study of Diabetes. Diabetes Care 28: 1250-1257 [Full text]  
  • Luscombe-Marsh, N. D, Noakes, M., Wittert, G. A, Keogh, J. B, Foster, P., Clifton, P. M (2005). Carbohydrate-restricted diets high in either monounsaturated fat or protein are equally effective at promoting fat loss and improving blood lipids. Am. J. Clin. Nutr. 81: 762-772 [Abstract] [Full text]  
  • Hu, G., Jousilahti, P., Barengo, N. C., Qiao, Q., Lakka, T. A., Tuomilehto, J. (2005). Physical Activity, Cardiovascular Risk Factors, and Mortality Among Finnish Adults With Diabetes. Diabetes Care 28: 799-805 [Abstract] [Full text]  
  • Drexel, H., Aczel, S., Marte, T., Benzer, W., Langer, P., Moll, W., Saely, C. H. (2005). Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?. Diabetes Care 28: 101-107 [Abstract] [Full text]  
  • Juutilainen, A., Kortelainen, S., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. (2004). Gender Difference in the Impact of Type 2 Diabetes on Coronary Heart Disease Risk. Diabetes Care 27: 2898-2904 [Abstract] [Full text]  
  • Bloomgarden, Z. T. (2004). Dyslipidemia and the Metabolic Syndrome. Diabetes Care 27: 3009-3016 [Full text]  
  • Brehm, A., Pfeiler, G., Pacini, G., Vierhapper, H., Roden, M. (2004). Relationship between Serum Lipoprotein Ratios and Insulin Resistance in Obesity. Clin. Chem. 50: 2316-2322 [Abstract] [Full text]  
  • Gaede, P., Pedersen, O. (2004). Intensive Integrated Therapy of Type 2 Diabetes: Implications for Long-Term Prognosis. Diabetes 53: S39-S47 [Abstract] [Full text]  
  • Aso, Y., Okumura, K.-i., Wakabayashi, S., Takebayashi, K., Taki, S., Inukai, T. (2004). Elevated Pregnancy-Associated Plasma Protein-A in Sera from Type 2 Diabetic Patients with Hypercholesterolemia: Associations with Carotid Atherosclerosis and Toe-Brachial Index. J. Clin. Endocrinol. Metab. 89: 5713-5717 [Abstract] [Full text]  
  • Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., Golden, S. H. (2004). Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus. ANN INTERN MED 141: 421-431 [Abstract] [Full text]  
  • Hori, M., Satoh, M., Furukawa, K., Sakamoto, Y.-i., Hakamata, H., Komohara, Y., Takeya, M., Sasaki, Y., Miyazaki, A., Horiuchi, S. (2004). Acyl-Coenzyme A:Cholesterol Acyltransferase-2 (ACAT-2) Is Responsible for Elevated Intestinal ACAT Activity in Diabetic Rats. Arterioscler. Thromb. Vasc. Bio. 24: 1689-1695 [Abstract] [Full text]  
  • Bagi, Z., Toth, E., Koller, A., Kaley, G. (2004). Microvascular dysfunction after transient high glucose is caused by superoxide-dependent reduction in the bioavailability of NO and BH4. Am. J. Physiol. Heart Circ. Physiol. 287: H626-H633 [Abstract] [Full text]  
  • Feher, M D (2004). Diabetes: preventing coronary heart disease in a high risk group. Heart 90: iv18-iv21 [Abstract] [Full text]  
  • Barrett-Connor, E., Giardina, E.-G. V., Gitt, A. K., Gudat, U., Steinberg, H. O., Tschoepe, D. (2004). Women and Heart Disease: The Role of Diabetes and Hyperglycemia. Arch Intern Med 164: 934-942 [Abstract] [Full text]  
  • Toth, P. P. (2004). High-Density Lipoprotein and Cardiovascular Risk. Circulation 109: 1809-1812 [Full text]  
  • Prisant, L. M. (2004). Clinical Trials and Lipid Guidelines for Type II Diabetes. J Clin Pharmacol 44: 423-430 [Abstract] [Full text]  
  • Yugar-Toledo, J. C., Tanus-Santos, J. E., Sabha, M., Sousa, M. G., Cittadino, M., Tacito, L. H. B., Moreno, H. Jr. (2004). Uncontrolled Hypertension, Uncompensated Type II Diabetes, and Smoking Have Different Patterns of Vascular Dysfunction. Chest 125: 823-830 [Abstract] [Full text]  
  • Mooradian, A. D., Haas, M. J., Wong, N. C.W. (2004). Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes. Diabetes 53: 513-520 [Abstract] [Full text]  
  • Tonkin, A (2004). The metabolic syndrome - a growing problem. Eur Heart J Suppl 6: A37-A42 [Abstract] [Full text]  
  • Alam, S., Stolinski, M., Pentecost, C., Boroujerdi, M. A., Jones, R. H., Sonksen, P. H., Umpleby, A. M. (2004). The Effect of a Six-Month Exercise Program on Very Low-Density Lipoprotein Apolipoprotein B Secretion in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 89: 688-694 [Abstract] [Full text]  
  • Schering, D., Kasten, S. (2004). The Link Between Diabetes and Cardiovascular Disease. Journal of Pharmacy Practice 17: 61-65 [Abstract]  
  • Bagi, Z., Koller, A., Kaley, G. (2004). PPAR{gamma} activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 286: H742-H748 [Abstract] [Full text]  
  • Hanefeld, M., Cagatay, M., Petrowitsch, T., Neuser, D., Petzinna, D., Rupp, M. (2004). Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25: 10-16 [Abstract] [Full text]  
  • Mohanlal, N., Holman, R. R. (2004). A Standardized Triglyceride and Carbohydrate Challenge: The oral triglyceride tolerance test. Diabetes Care 27: 89-94 [Abstract] [Full text]  
  • Protopsaltis, I. D., Konstantinopoulos, P. A., Kamaratos, A. V., Melidonis, A. I. (2004). Comparative Study of Prognostic Value for Coronary Disease Risk Between the U.K. Prospective Diabetes Study and Framingham Models. Diabetes Care 27: 277-278 [Full text]  
  • (2004). Prevention or Delay of Type 2 Diabetes. Diabetes Care 27: s47-47 [Full text]  
  • (2004). Dyslipidemia Management in Adults With Diabetes. Diabetes Care 27: s68-71 [Full text]  
  • Bloomgarden, Z. T. (2003). Approaches to Cardiovascular Disease and Its Treatment. Diabetes Care 26: 3342-3348 [Full text]  
  • Salmasi, A.-M., Jepson, E., Grenfell, A., Kirollos, C., Dancy, M. (2003). The Degree of Albuminuria Is Related to Left Ventricular Hypertrophy in Hypertensive Diabetics and Is Associated with Abnormal Left Ventricular Filling: A Pilot Study. ANGIOLOGY 54: 671-678 [Abstract]  
  • Goldberg, R. B. (2003). Statin Treatment in Diabetic Subjects: What the Heart Protection Study Shows. Clin. Diabetes 21: 151-152 [Full text]  
  • Folsom, A. R., Chambless, L. E, Duncan, B. B., Gilbert, A. C., Pankow, J. S., the Atherosclerosis Risk in Communities Study Inve, (2003). Prediction of Coronary Heart Disease in Middle-Aged Adults With Diabetes. Diabetes Care 26: 2777-2784 [Abstract] [Full text]  
  • Haber, C. A., Lam, T. K. T., Yu, Z., Gupta, N., Goh, T., Bogdanovic, E., Giacca, A., Fantus, I. G. (2003). N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am. J. Physiol. Endocrinol. Metab. 285: E744-E753 [Abstract] [Full text]  
  • Bagi, Z., Koller, A., Kaley, G. (2003). Superoxide-NO interaction decreases flow- and agonist-induced dilations of coronary arterioles in Type 2 diabetes mellitus. Am. J. Physiol. Heart Circ. Physiol. 285: H1404-H1410 [Abstract] [Full text]  
  • Dhatariya, K. (2003). Type 2 diabetes is cardiovascular disease. JRSM 96: 371-372 [Full text]  
  • Parmar, M. S (2003). Two groups were different in cardiovascular risk study. BMJ 327: 290-291 [Full text]  
  • Wagner, A. M., Jorba, O., Bonet, R., Ordonez-Llanos, J., Perez, A. (2003). Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia. J. Clin. Endocrinol. Metab. 88: 3212-3217 [Abstract] [Full text]  
  • Stojanovic, N.D., Kwong, P., Byrne, D.J., Arnold, A., Jagroop, I.A., Nair, D., Press, M., Hurel, S., Mikhailidis, D.P., Prelevic, G.M. (2003). The Effects of Transdermal Estradiol Alone or with Cyclical Dydrogesterone on Markers of Cardiovascular Disease Risk in Postmenopausal Women with Type 2 Diabetes: A Pilot Study. ANGIOLOGY 54: 391-399 [Abstract]  
  • Goff, D. C. Jr. (2003). The ALLHAT Study. Clin. Diabetes 21: 102-104 [Full text]  
  • Brandle, M., Davidson, M. B., Schriger, D. L., Lorber, B., Herman, W. H. (2003). Cost Effectiveness of Statin Therapy for the Primary Prevention of Major Coronary Events in Individuals With Type 2 Diabetes. Diabetes Care 26: 1796-1801 [Abstract] [Full text]  
  • King, D. E., Mainous, A. G. III, Buchanan, T. A., Pearson, W. S. (2003). C-Reactive Protein and Glycemic Control in Adults With Diabetes. Diabetes Care 26: 1535-1539 [Abstract] [Full text]  
  • Lee, S.-J., Campos, H., Moye, L. A., Sacks, F. M. (2003). LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients. Arterioscler. Thromb. Vasc. Bio. 23: 853-858 [Abstract] [Full text]  
  • Kitas, G. D., Erb, N. (2003). Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology (Oxford) 42: 607-613 [Full text]  
  • Safford, M., Eaton, L., Hawley, G., Brimacombe, M., Rajan, M., Li, H., Pogach, L. (2003). Disparities in Use of Lipid-Lowering Medications Among People With Type 2 Diabetes Mellitus. Arch Intern Med 163: 922-928 [Abstract] [Full text]  
  • Inzucchi, S. E., Amatruda, J. M. (2003). Lipid Management in Patients With Diabetes: Translating guidelines into action. Diabetes Care 26: 1309-1311 [Full text]  

Rapid Responses:

Read all Rapid Responses

To find the actual risk factors for coronary artery disease in non-insulin dependent diabetes mellitus, influence of the LADA patients should be removed
Arya K Kumarasena
bmj.com, 26 Feb 2008 [Full text]